Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Brivaracetam Tablet and Dry Syrup in Healthy Japanese Men
NCT05315947Phase 1Completed
- Sponsor
- UCB
- Start
- Apr 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brivaracetam in epilepsy (2 arms), sponsored by UCB. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve From 0 to Last Quantifiable Concentration at 48 hours. Started Apr 2022; status: completed.
02
Drugs
brivaracetam
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05315947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05315947.